Dengue is one of the most frequently transmitted viral infections globally which creates a serious burden to the healthcare system in many countries in the tropical and subtropical regions. To date, no vaccine has demonstrated balanced protection against the four dengue serotypes. Dengvaxia as the only vaccine that has been licensed for use in endemic areas has shown an increased risk in dengue-naïve vaccines to develop severe dengue. A crucial element in protection from dengue infection is the neutralizing antibody responses. Therefore, the identification of protective linear B-cell epitopes can guide vaccine design and facilitate the development of monoclonal antibodies as dengue therapeutics. This review summarizes the identification of dengue B-cell epitopes within the envelope (E) protein of dengue that can be incorporated into peptide vaccine constructs. These epitopes have been identified through approaches such as bioinformatics, three-dimensional structure analysis of antibody-dengue complexes, mutagenesis/alanine scanning and escape mutant studies. Additionally, the therapeutic potential of monoclonal antibodies targeting the E protein of dengue is reviewed. This can provide a basis for the design of future dengue therapies.

登革热是全球传播最频繁的病毒感染之一，它给热带和亚热带地区许多国家的医疗保健系统带来了严重负担。迄今为止，没有疫苗显示出对四种登革热血清型的平衡保护。Dengvaxia 作为唯一获准在流行地区使用的疫苗，已显示登革热初治疫苗发展为重症登革热的风险增加。保护免受登革热感染的一个关键因素是中和抗体反应。因此，保护​​性线性 B 细胞表位的鉴定可以指导疫苗设计并促进单克隆抗体作为登革热疗法的开发。这篇综述总结了登革热包膜 (E) 蛋白中登革热 B 细胞表位的鉴定，这些表位可以并入肽疫苗构建体中。这些表位已通过生物信息学、抗体-登革热复合物的三维结构分析、诱变/丙氨酸扫描和逃逸突变研究等方法进行鉴定。此外，还回顾了针对登革热 E 蛋白的单克隆抗体的治疗潜力。这可以为未来登革热疗法的设计提供基础。综述了靶向登革热E蛋白的单克隆抗体的治疗潜力。这可以为未来登革热疗法的设计提供基础。综述了针对登革热E蛋白的单克隆抗体的治疗潜力。这可以为未来登革热疗法的设计提供基础。